Zobrazeno 1 - 3
of 3
pro vyhledávání: '"B. Jagan Nathan"'
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 15, Iss 2, Pp FE01-FE04 (2021)
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 20
Externí odkaz:
https://doaj.org/article/dd9fcaf543044995bc8398b387bec6c2
Autor:
Vishnu Shankar, Pearlsy Grace Rajan, Yuvaraj Krishnamoorthy, Damal Kandadai Sriram, Melvin George, S. Melina I. Sahay, B. Jagan Nathan
Publikováno v:
Irish Journal of Medical Science
Background Development of a prediction model using baseline characteristics of COVID-19 patients at the time of diagnosis will aid us in early identification of the high-risk groups and devise pertinent strategies accordingly. Hence, we did this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e95a2bac34379f0b58c04372332143
https://doi.org/10.1007/s11845-021-02876-w
https://doi.org/10.1007/s11845-021-02876-w
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 15, Iss 2, Pp FE01-FE04 (2021)
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b945cb23f64a6f0f125b960c0205fd8
https://doi.org/10.7860/jcdr/2021/46060.14550
https://doi.org/10.7860/jcdr/2021/46060.14550